Clinical trials
Hemophilia A clinical trials
Below are recruiting hemophilia a clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06727669Recruiting
Long-term study of blood clotting and bleeding disorders
This study observes patients with blood clotting or bleeding disorders over time to collect health information and improve care.
Beijing, Beijing MunicipalityAges Any age - NCT07414511Recruiting
Hemophilia A research study for pregnant families
This study follows pregnant people who carry a severe hemophilia A gene and their babies after birth. It looks at how hemophilia A is passed down and how it affects families, with the goal of improving understanding and care.
Seattle, WashingtonAges Any age - NCT06349473RecruitingPhase 1
Study of SR604 in healthy people and those with bleeding disorders
This study tests a new drug called SR604 to see if it is safe and how it works in the body. It is for healthy men and for people with hemophilia A, hemophilia B, or factor VII deficiency who have frequent bleeding or are on preventive treatment.
Glendale, CaliforniaAges 18–60 - NCT05611801RecruitingPhase 3
Study medicine for children with hemophilia A or B
This trial tests a study medicine (marstacimab) for children with severe hemophilia A or B, to see if it can help prevent or reduce bleeding episodes. It may be an option for children who do not have certain other health conditions.
Salt Lake City, UtahAges 1–17 - NCT02912143Recruiting
Hemophilia pediatric research registry database
This trial is a research registry that enrolls children with hemophilia A or B to collect health information. It may help researchers better understand bleeding risk and treatment needs over time.
Frankfurt am Main, HesseAges Up to 18 years - NCT05802836Recruiting
Tracking an antibody response in severe hemophilia A on emicizumab
This trial studies how your body’s anti-factor VIII antibodies change while you are treated with emicizumab for severe hemophilia A. The goal is to better understand the immune response during treatment and whether it relates to how well therapy works.
Frankfurt am Main, HesseAges Any age - NCT03327779Recruiting
Bleeding disorders registry for blood-clotting conditions
This study is a registry that collects information about people with bleeding disorders like hemophilia A or B and von Willebrand disease. The goal is to better understand these conditions and improve care across participating treatment centers.
Montreal, QuebecAges Any age - NCT07644832RecruitingPhase 1/Phase 2
New Blood-Clotting Injection for Hemophilia and Factor VII Deficiency
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
ChangshaAges 18–65 - NCT06820515Recruiting
Blood disorder patient registry for all ages
This study is a registry (a large database) that collects information from people who have or may have a blood disorder. It helps researchers learn more about these conditions and improve care.
Hickory, North CarolinaAges Any age - NCT05568719RecruitingPhase 3
Testing gene therapy for hemophilia A or B
This Phase 3 trial is checking how safe and effective two gene therapies are for people with hemophilia A or hemophilia B. It only includes people who already received the study medicines through specific Pfizer studies, so it’s mainly for that existing participant group.
Rancho Cordova, CaliforniaAges 18 years+ - NCT05145127RecruitingPhase 3
Marstacimab follow-up study for people with hemophilia
This Phase 3 study looks at how well and how safely marstacimab works over a longer follow-up period. You may join if you already finished a related parent study for hemophilia, and you can keep up with frequent visits and lab tests.
Iowa City, IowaAges 1–74 - NCT04647227RecruitingPhase 4
SEVENFACT® to reduce bleeding in hemophilia with inhibitors
This trial studies whether SEVENFACT® can reduce bleeding episodes in people with hemophilia A or B who have inhibitors (proteins that make standard treatments less effective). It also tests how well people can track bleeding and medicine use during the study.
Phoenix, ArizonaAges 12–100 - NCT04645199Recruiting
Long-term follow-up study for blood and bone marrow diseases
This study is collecting long-term follow-up information from people diagnosed with certain blood and bone marrow conditions. It may help doctors understand what happens over time and improve future care, but you’re mainly contributing data rather than receiving a new treatment.
Tianjin, Tianjin MunicipalityAges Any age - NCT06703606RecruitingPhase 1
Switching from Emicizumab to Marstacimab for Severe Hemophilia A
This study tests if switching from emicizumab to a new medicine called marstacimab is safe and effective for people with severe hemophilia A. You must have been on emicizumab for at least 6 months and not have a history of blood clots or heart disease.
La Jolla, CaliforniaAges 12–74 - NCT04676048RecruitingPhase 1/Phase 2
Gene therapy study for adults with hemophilia A
This Phase 1/2 study tests a one-time gene therapy (ASC618) to help the body make clotting factor for people with hemophilia A. It may reduce bleeding and the need for factor infusions, but you must meet several safety and eligibility checks.
Little Rock, ArkansasAges 18 years+ - NCT07867834Recruiting
Telemedicine for better hemophilia care
This study tests whether using a smartphone app to track treatment and check in with doctors can improve how well hemophilia is managed. It may help make your treatment plan more personal and effective.
MilanAges 18 years+ - NCT04567511RecruitingPhase 4
Hemlibra for mild hemophilia A patients
This trial studies Hemlibra (emicizumab) in people with mild congenital hemophilia A to see how well it works and what safety issues may occur. It may help reduce bleeding in patients who meet the study’s specific health and safety requirements.
Indianapolis, IndianaAges 5–45 - NCT05981274Recruiting
Bone health study of a long-acting factor VIII for hemophilia A
This study tests whether a long-acting factor VIII medicine (rFVIIIFc) helps protect the bones and joints of people with hemophilia A. If you have severe or moderate hemophilia with joint damage and are already on this treatment, you may be able to join.
Taipei, Neihu Dist.Ages Any age - NCT06352216Recruiting
Joint inflammation in hemophilia A patients
This study looks at how many adults with moderate or severe hemophilia A have inflammation in their joints (synovitis). It aims to better understand joint health in people with hemophilia A, including those with inhibitors or joint replacements.
Bonn, North Rhine-WestphaliaAges 18 years+ - NCT07851922Recruiting
Walking and balance tests for people with hemophilia
This study checks if two simple walking and balance tests are reliable for people with hemophilia who have had joint bleeds. It may help doctors better track joint health and function.
VanAges 18–65 - NCT07787091RecruitingPhase 1/Phase 2
First study of ARD001 in healthy people and those with hemophilia A
This study tests a new medicine, ARD001, for the first time in humans. It aims to see if the drug is safe and how the body handles it, and it is also being studied in people with hemophilia A to find a safe dose for future trials.
SingaporeAges 21–45 - NCT07692217Recruiting
Joint health study for severe hemophilia A patients on new therapies
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Dallas, TexasAges 6 months+ - NCT07682519Recruiting
Home vs. in-person rehab for hemophilia pain
This study compares a rehabilitation program you can do at home using video calls (telerehabilitation) with in-person rehabilitation sessions. The goal is to see if the home-based option works as well as office visits for reducing chronic joint pain in adults with hemophilia.
Santiago, Santiago MetropolitanAges 18–60 - NCT07582276Recruiting
Bone health in men with severe hemophilia a on two treatments
This study looks at how two different hemophilia A treatments affect bone health over time. It tests if one medicine is better at keeping bones strong than the other.
Little Rock, ArkansasAges 30–50
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Hemophilia A trials by city
Studies with a site in or near these metro areas.
Hemophilia A trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for hemophilia a?
- Yes. Clin2 currently lists 87 recruiting hemophilia a studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hemophilia a trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hemophilia a trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.